Compositions and methods for treatment of diabetic retinopathy
AssigneeSARcode Corporation
InventorsJohn Burnier, Thomas Gadek, Charles Semba
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds and methods for the treatment of diabetic retinopathy. In particular, LFA-1 antagonists are described herein to be used in the treatment of diabetic retinopathy. One aspect of the invention provides for diagnosis of diabetic retinopathy and administration of a LFA-1 antagonist, after the patient is diagnosed with diabetic retinopathy.
Claims63
A method of treating a subject suffering from diabetic retinopathy comprising administering to said subject in need thereof a therapeutically effective amount of a therapeutic agent which inhibits the interaction of LFA-1 and an ICAM.
A method of treating a subject suffering from macular edema comprising administering to said subject in need thereof a therapeutically effective amount of a therapeutic agent which inhibits the interaction of LFA-1 and an ICAM, thereby reducing and/or preventing macular edema in an eye of said subject.
A method of treating diabetic retinopathy in an subject comprising performing a diabetic retinopathy diagnostic test on said subject;
- determining whether said subject suffers from diabetic retinopathy based on the results of said diagnostic test;
- and upon diagnosis of said diabetic retinopathy, administering to said subject an effective amount of a lymphocyte function associated antigen-1 (LFA-1) antagonist in a pharmaceutically acceptable formulation.
A method of reducing and/or preventing post-operative ocular inflammation in a subject suffering from diabetes comprising administering to said subject in need thereof a therapeutically effective amount of a LFA-1 antagonist, thereby reducing and/or preventing post-operative inflammation in an eye of said subject.
Dependencies are inferred from the claim text.